



Relburn-Metabolomics, Inc.  
Westfield, NJ 07090

## Relburn-Metabolomics to Present at Biotech Showcase 2015

**Westfield, NJ – January 7, 2015** -- Relburn-Metabolomics, Inc., an emergent life-science company focused on improving health for patients with metabolic and inflammatory diseases, will update the Company's scientific and development progress at Biotech Showcase 2015 taking place in San Francisco, CA on January 12-14, 2015.

Raymond P. Warrell, Jr., M.D. Chief Executive Officer of Relburn, will provide an overview of the Company's business and activities during this presentation and will be available to meet with registered conference investors. Meetings outside the conference may be scheduled by directly contacting Relburn Investor Relations (see below). Presentation information follows:

**Event:** Biotech Showcase™ 2015  
**Date:** Wednesday, January 14, 2015  
**Time:** 10:45 am (Pacific Time)  
**Location:** Parc 55 Wyndham Hotel, San Francisco, CA

### About Relburn-Metabolomics®

Relburn's lead program is focused on the development of transforming therapy for chronic gout – a disease whose prevalence is doubling every 10 years and currently afflicts 16 million subjects in major markets. Gout is caused by excess uric acid (UA) in blood and connective tissues that leads to painful destructive arthritis, kidney failure, and possibly accelerated cardiovascular disease. Standard treatment seeks to reduce UA production or promote UA excretion. Benchmark drugs with these activities are allopurinol and lesinurad, respectively. Unlike other anti-gout drugs, Relburn compounds exert bifunctional activities on both production *and* excretion of UA. Targeting enzymes that mediate these activities, Relburn compounds are approximately 10-fold more potent than these benchmark drugs – effects that have yielded exceptional clinical activity.

Gout treatment is focused on reducing UA to target serum levels less than 6 mg/dL. Clinical trials with the Relburn prototype drug in more than 350 patients showed that serum UA was routinely reduced to levels less than 1.0 mg/dL. With this "clinical proof-of-concept", Relburn has synthesized compound libraries that may further enhance clinical activity potency and reduce potential side-effects. These compounds are

covered by composition patent applications that are exclusively owned by the Company. Monotherapy with Relburn drugs may replace standard 1<sup>st</sup>-line treatments for gout and meaningfully improve clinical outcomes for patients.

Further information about Relburn-Metabolomics<sup>®</sup> Inc. can be accessed at: [www.relburn.com](http://www.relburn.com).

### **About Biotech Showcase 2015**

Biotech Showcase™ is an investor and partnering conference that facilitates interaction between life sciences companies, investors, and pharma executives coincident with one of the largest healthcare investor conferences. These conferences and meetings are widely viewed as setting the investment tone for the coming year.

*This press release may contain forward-looking statements with respect to business conducted by Relburn-Metabolomics, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets, or future developments, and are not statements of historical fact. The words “potentially”, “anticipates”, “expects”, and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements, and there are a number of factors that could cause actual results and developments to differ materially.*

### **Relburn investor information:**

Relburn Investor Relations, [Tiberend Strategic Advisors, Inc.](http://www.tiberend.com)  
Joshua Drumm, PhD.: [jdrumm@tiberend.com](mailto:jdrumm@tiberend.com)  
Tel: (212) 375-2664

**Relburn company information:** [info@relburn.com](mailto:info@relburn.com)

**SOURCE:** Relburn-Metabolomics<sup>®</sup> Inc.